Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
Clinical Trial Details
Research Study Summary
A phase 2, multicenter, double-blind placebo-controlled comparator study of 2 doses of LY2140023 versus placebo in patients with DSM-IV-TR Schizophrenia.
The primary purpose of your participation in this study is to help answer the following research question(s), and not to provide you treatment for your condition:
- Whether LY2140023 can help subjects/patients with schizophrenia.
- Whether LY2140023 can help subjects/patients with schizophrenia who have certain DNA.
You must be willing and able to stay in the hospital for a minimum of 21 days.
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.